Table 2.
Baseline characteristics of study subjects who withdrew from the study or were lost to follow-up (N = 9)
| Clinical characteristics | (N=9) | |
|---|---|---|
| Age in years, mean (SD) | 63.2 | (14.5) |
| Rheumatoid arthritis disease duration in years, mean (SD) | 13 | (14.3) |
| Female gender, n (%) | 9 | (100.0) |
| Caucasian race, n (%) | 7 | (77.8) |
| Rheumatoid factor/Cyclic citrullinated peptide positive, n (%) | 2 | (22.2) |
| Disease-modifying antirheumatic drug use, n (%) | ||
| Non-biologic | 3 | (33.3) |
| Biologic | 5 | (55.6) |
| Oral glucocorticoid use, n (%) | 1 | (11.1) |
| Meets American College of Rheumatology 2010 criteria, n (%) | 5 | (55.6) |
| Swollen joint count, median (IQR) | 1 | (1) |
| Tender joint count, median (IQR) | 8 | (14) |
| C-reactive protein, median (IQR) | 1.9 | (3) |
| Disease Activity Score in 28 joints – C-reactive Protein, median (IQR) | 3.3 | (1.6) |
| Tender point count, median (IQR) | 11 | (14) |
| Hospital Anxiety and Depression Scale Anxiety score, mean (SD) | 5.4 | (5) |
| Hospital Anxiety and Depression Scale Depression score, mean (SD) | 3.2 | (2) |
| Medical Outcomes Study Sleep Problems Index II score, mean (SD) | 42.5 | (17.7) |
| Pain Catastrophizing Scale score, mean (SD) | 25.8 | (9.2) |
Abbreviations: SD, standard deviation; IQR, interquartile range.